CSWYF OTC
China Shineway Pharmaceutical Group Limited
1W: +0.0%
1M: -6.9%
3M: -12.7%
YTD: -12.7%
1Y: -12.7%
3Y: +16.9%
5Y: +3.9%
$1.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$10.0B
+644.1% ▲
5Y CAGR: +57.9%
Total Liabilities
$2.6B
+619.3% ▲
5Y CAGR: +69.0%
Shareholders Equity
$7.5B
+653.0% ▲
5Y CAGR: +55.2%
Cash & Investments
$6.5B
+9.8% ▲
5Y CAGR: +62.9%
Total Debt
$347M
+15.0% ▲
5Y CAGR: +42.9%
Net Debt
-$5.8B
-3.7% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $649M | $660M | $725M | $5.9B | $6.1B |
| Short-Term Investments | $0 | $0 | $0 | $20M | $350M |
| Cash & ST Investments | $649M | $660M | $725M | $5.9B | $6.5B |
| Net Receivables | $3.3B | $136M | $150M | $1.3B | $1.2B |
| Inventory | $68M | $92M | $95M | $898M | $813M |
| Other Current Assets | $1.1B | $825M | $1.0B | $1.3B | $0 |
| Total Current Assets | $844M | $894M | $975M | $8.2B | $8.6B |
| Property, Plant & Equip. | $213M | $196M | $175M | $1.2B | $1.2B |
| Goodwill & Intangibles | $37M | $62M | $55M | $199M | $189M |
| Long-Term Investments | -$16M | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $21M | -$26M | -$24M | $0 | $0 |
| Total Non-Current Assets | $259M | $236M | $208M | $1.4B | $1.4B |
| Total Assets | $1.1B | $1.1B | $1.2B | $1.3B | $10.0B |
| — Liabilities — | |||||
| Accounts Payable | $164M | $229M | $309M | $485M | $403M |
| Short-Term Debt | $369M | $0 | $0 | $300M | $330M |
| Deferred Revenue | $10M | $13M | $22M | $0 | $0 |
| Other Current Liabilities | -$934M | $117M | $973M | $127M | $102M |
| Total Current Liabilities | $183M | $172M | $239M | $2.4B | $2.4B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | -$222M | $0 | $0 | $0 | $0 |
| Total Non-Current Liabilities | $3M | $5M | $26M | $106M | $125M |
| Total Liabilities | $186M | $177M | $266M | $358M | $2.6B |
| — Equity — | |||||
| Common Stock | $13M | $14M | $13M | $12M | $88M |
| Retained Earnings | $812M | $842M | $834M | $6.3B | $6.7B |
| Accumulated OCI | $85M | $95M | $93M | -$70M | $0 |
| Total Stockholders Equity | $886M | $926M | $917M | $992M | $7.5B |
| Total Liabilities & Equity | $1.1B | $1.1B | $1.2B | $1.3B | $10.0B |
| — Key Metrics — | |||||
| Total Debt | $60M | $2M | $1M | $301M | $347M |
| Net Debt | -$589M | -$657M | -$724M | -$5.6B | -$5.8B |
| Total Investments | -$15M | $0 | $0 | $20M | $350M |